An Overview of the Multiple Myeloma Program
Mar 22, 2021 1:30 PM
The Multiple Myeloma Program at the Huntsman Cancer Institute is a growing and dynamic group that includes five physicians, a talented team of APCs, and over 25 support staff. We focus on the treatment of patients with plasma cell dyscrasias, including monoclonal gammopathy of clinical significance (MGCS), smoldering myeloma, Waldenstrom macroglobulinemia, POEMS, amyloidosis, and multiple myeloma. With our collection of subspecialty clinics, we strive to provide personalized, state-of-the-art care with compassion and expertise.
Myeloma is a very treatable disease, but is currently considered incurable. The present median survival is approximately 5 years, however, patients with standard risk disease can survive 10+ years while those with highly aggressive disease on average live less than 2 years. Historically, there were very few drugs to treat multiple myeloma, but this has changed dramatically over the past two decades. The armamentarium is now relatively vast, highlighted by the fact that there were five FDA approvals for myeloma in 2020.
Our program is dedicated to developing novel immunotherapeutic approaches and currently have 12 clinical trials available for patients with smoldering myeloma, newly diagnosed and relapsed and refractory disease. These trials are investigating monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, viral oncolytics, targeted therapy for patients with specific chromosomal translocation, and chimeric antigen receptor (CAR) T-cells. Ultimately, we are dedicated to offering our patients the very highest quality of clinical trial options at every stage of their disease process.
We continue to expand our horizons beyond the clinic as we grow our collaborative scientific projects across the university, including novel drug development with the Department of Pharmaceutical Chemistry, multi-disciplinary investigation of bone-related disease with the Division of Oncology and Department of Engineering, and establishment of patient derived organoid models with the Department of Medicinal Chemistry. In addition, we are working to establish an education curriculum to teach and train providers and trainees across the University of Utah Health system and Huntsman Cancer Institute.
We are encouraged by our accomplishments, and are excited for what the future holds. We are committed to be an integral part of the University, and will continue to utilize our resources to move our field towards the elusive cure!
To make a referral to this clinic, please use one of the following options:
- Submit a referral in EPIC to AMB REFERRAL TO ONCOLOGY BMT MULTIPLE MYELOMA (CN0350)
- Call 801-213-5723 to speak with our New Patient Coordinator to schedule
- For outside providers, please call 801-213-5723, or fax referrals to 801-213-0600